The trend to a higher rate of vessel recanalization in cardioembolic stroke with thrombolytic therapies might be as well explained for low plasma levels of endogenous tPA and its inhibitor (plasminogen activator inhibitor-1 or PAI-1) since the raise of these markers have been related to increased risk of atherothrombotic ischemic events such as stroke or myocardial infarction [62]. This evidence concerns the gene SERPINE1 and Stroke.